STOCK TITAN

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced the release of its fourth quarter and 2023 financial results on March 13, 2024. The company will host a conference call on March 14, 2024, to discuss the results and provide a corporate update.
Positive
  • None.
Negative
  • None.

ASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its fourth quarter and 2023 financial results after the market closes on Wednesday, March 13, 2024.

The Company will host a conference call and webcast at 8:30am ET on Thursday, March 14, 2024.   The call will include a discussion of fourth quarter and 2023 financial results and a corporate update.  

The live call can be accessed by dialing 1-800-603-0527 (domestic) or 1-412-317-0688 (international).

The live and archived webcast of the call will also be available on the Quoin Pharmaceuticals website under the Investors section or by following this link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=ZmehVyN5

About Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.

For further information, contact:
Investor Relations
PCG Advisory
Stephanie Prince
sprince@pcgadvisory.com
(646) 863-6341


Quoin Pharmaceuticals will release its fourth quarter and 2023 financial results after the market closes on Wednesday, March 13, 2024.

The conference call to discuss the financial results will take place at 8:30am ET on Thursday, March 14, 2024.

The live call can be accessed by dialing 1-800-603-0527 (domestic) or 1-412-317-0688 (international).

The webcast of the call will be available on the Quoin Pharmaceuticals website under the Investors section or through the link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=ZmehVyN5
Quoin Pharmaceuticals Ltd

NASDAQ:QNRX

QNRX Rankings

QNRX Latest News

QNRX Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Israel
23 Hataas St

About QNRX

cellect biotechnology was founded in 2011 with a mission to become a global leader in the next generation of cellular therapies by developing innovative solutions for immune system regeneration. achieving higher selectivity, greater specificity and decreased toxicity, cellect envisions its products becoming an integral and essential part of bone marrow transplantation (bmt), as well as integrated into many aspects of regenerative medicine.